{
    "clinical_study": {
        "@rank": "137985", 
        "arm_group": [
            {
                "arm_group_label": "metformin glycinate", 
                "arm_group_type": "Experimental", 
                "description": "620mg tablets of metformin glycinate: 1 tablet by mouth at night for 3 days, 1 tablet  in the morning and evening for 3 days, 1 tablet in the morning and 2 tablets in the evening for 3 days and 2 tablets in the evening and 2 tablets in the morning until the end of the study.\nTotal study dose: 1240mg every 12 hours."
            }, 
            {
                "arm_group_label": "metformin hydrochloride", 
                "arm_group_type": "Active Comparator", 
                "description": "500mg tablets of metformin hydrochloride:1 tablet by mouth at night for 3 days, 1 tablet in the morning and evening for 3 days, 1 tablet in the morning and 2 tablets in the evening for 3 days and 2 tablets in the evening and 2 tablets in the morning until the end of the study.\nTotal study dose: 1000mg every 12 hours."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to evaluate the effect of metformin glycinate vs metformin\n      hydrochloride on postprandial lipemia. 72 patients will be included, they will be randomized\n      and assigned into one of the two treatment groups: metformin glycinate 1240 mg BID or\n      metformin hydrochloride 1000 mg BID (36 patients per group). The  patients will be followed\n      for 4 months.\n\n      Blood count, blood chemistry, liver profile, lipid profile, HbA1c, apolipoprotein B,\n      oxidized LDL, fibroblast growth factor 21, leptin, adiponectin, C-reactive protein, free\n      fatty acids, fibrinogen, Goodpasture Binding Protein (GPBP) and antioxidant activity of\n      plasma will be measured at baseline and 4 months.\n\n      Additionally, after a structured meal, the following parameters will be measured: glucose,\n      insulin, triglycerides, apolipoprotein B and oxidized LDL. (baseline and 4 months).\n      Throughout the study adverse events will be documented."
        }, 
        "brief_title": "Efficacy Study of Metformin Glycinate on Postprandial Lipemia", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients of both sexes\n\n          -  Between 35 and 65 years old\n\n          -  Patients with type 2 diabetes within two years of diagnosis according to the ADA\n             criteria\n\n          -  Overweight patients (BMI between 25.5 and 29.9 kg/m2) or with grade 1 obesity  (BMI\n             between 30.0 and 34.9 kg/m2), according to WHO classification\n\n          -  Low HDL levels: <50 in women and <40 mg/dL in men\n\n          -  Hypertriglyceridemia: >150 and less than 300 mg/dL\n\n          -  Patients who had not taken antidiabetes drug treatment or with diet and exercise\n             treatment, or with metformin or DPP4 inhibitor monotherapy\n\n          -  HbA1c between 6.5 and 8.5%.\n\n          -  Creatinine clearance >60 ml/min (calculated by Cockcroft and Gault)\n\n          -  Informed consent form signed.\n\n          -  Women using contraception.\n\n        Exclusion Criteria:\n\n          -  Patients with other types of diabetes (type 1, LADA, MODY, etc.).\n\n          -  Patients with primary dyslipidemia.\n\n          -  Patients with poorly substituted hypothyroidism TSH > 5 mU/mL.\n\n          -  Patients hospitalized in the last month.\n\n          -  Patients with a disease of poor short-term prognosis\n\n          -  Patients with autoimmune or rheumatic diseases.\n\n          -  Patients with acute infection or febrile illness.\n\n          -  History of chronic liver disease or ALT or AST \u2265 2.0 times the upper limit of normal,\n             or GGT \u2265 3 times the upper limit of normal.\n\n          -  Patients with any other chronic disease, for example: HIV, rheumatic diseases.\n\n          -  Pregnant or positive pregnancy test.\n\n          -  Women who are breastfeeding.\n\n          -  Patients in another research project."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02064881", 
            "org_study_id": "DMMET_LP001"
        }, 
        "intervention": [
            {
                "arm_group_label": "metformin glycinate", 
                "intervention_name": "Metformin glycinate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "metformin hydrochloride", 
                "intervention_name": "Metformin Hydrochloride", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Postprandial lipemia", 
            "Diabetes", 
            "Metformin glycinate", 
            "oxidized LDL"
        ], 
        "lastchanged_date": "February 14, 2014", 
        "location": {
            "contact": {
                "email": "gomezperezfco@gmail.com", 
                "last_name": "Francisco G\u00f3mez, Doctor", 
                "phone": "55133891"
            }, 
            "contact_backup": {
                "email": "palomaalmeda@yahoo.com", 
                "last_name": "Paloma Almeda, Doctor", 
                "phone": "56554523"
            }, 
            "facility": {
                "address": {
                    "city": "M\u00e9xico", 
                    "country": "Mexico", 
                    "state": "Distrito Federal", 
                    "zip": "14000"
                }, 
                "name": "Instituto Nacional de Ciencias M\u00e9dicas Y Nutrici\u00f3n Salvador Zubir\u00e1n"
            }, 
            "investigator": {
                "last_name": "Francisco J G\u00f3mez, Doctor", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Mexico"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Metformin Glycinate on Postprandial Lipemia, Glycemic Control and Oxidation Markers in Type 2 Diabetes Patients", 
        "overall_official": {
            "affiliation": "Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n", 
            "last_name": "Francisco J G\u00f3mez, Doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Mexico: Federal Commission for Protection Against Health Risks", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in postprandial lipemia at 4 months", 
            "safety_issue": "No", 
            "time_frame": "baseline, 4 months"
        }, 
        "reference": [
            {
                "PMID": "22517736", 
                "citation": "Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012 Jun;35(6):1364-79. doi: 10.2337/dc12-0413. Epub 2012 Apr 19. Review. Erratum in: Diabetes Care. 2013 Feb;36(2):490."
            }, 
            {
                "PMID": "9742977", 
                "citation": "[No authors listed] Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):854-65. Erratum in: Lancet 1998 Nov 7;352(9139):1557."
            }, 
            {
                "PMID": "21471135", 
                "citation": "Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, Fosb\u00f8l EL, K\u00f8ber L, Norgaard ML, Madsen M, Hansen PR, Torp-Pedersen C. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011 Aug;32(15):1900-8. doi: 10.1093/eurheartj/ehr077. Epub 2011 Apr 6. Erratum in: Eur Heart J. 2012 May;33(10):1183."
            }, 
            {
                "PMID": "15699279", 
                "citation": "Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005 Feb 8;111(5):583-90."
            }, 
            {
                "PMID": "21098347", 
                "citation": "Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S, Ravaud P, Marre M, Porath A, Bhatt DL, Steg PG; Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010 Nov 22;170(21):1892-9. doi: 10.1001/archinternmed.2010.409."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02064881"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in oxidized LDL at 4 months", 
                "safety_issue": "No", 
                "time_frame": "baseline, 4 months"
            }, 
            {
                "measure": "Change in FGF-21 levels at 4 months", 
                "safety_issue": "No", 
                "time_frame": "baseline, 4 months"
            }, 
            {
                "measure": "Change in A1C at 4 months", 
                "safety_issue": "No", 
                "time_frame": "baseline, 4 months"
            }, 
            {
                "measure": "Change in alanine aminotransferase at 4 months", 
                "safety_issue": "No", 
                "time_frame": "baseline, 4 months"
            }, 
            {
                "measure": "Change in uric acid at 4 months", 
                "safety_issue": "No", 
                "time_frame": "baseline, 4 months"
            }, 
            {
                "measure": "Number of Participants with Serious and Non-Serious Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 4 months"
            }
        ], 
        "source": "Laboratorios Silanes S.A. de C.V.", 
        "sponsors": {
            "collaborator": {
                "agency": "Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Laboratorios Silanes S.A. de C.V.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}